Jagsonpal Pharmaceuticals Limited has received a significant tax demand notice from the Income Tax Department, requiring disclosure under regulatory obligations. The pharmaceutical company informed stock exchanges about this development on March 13, 2026, in compliance with SEBI listing requirements.

Tax Assessment Details

The Income Tax Department's Faceless Assessment Unit issued an assessment order under sections 143(3) and 144B of the Income Tax Act 1961, dated March 12, 2026. This resulted in a tax demand notice under Section 156 of the Income Tax Act for Assessment Year 2024-25.

Reason for Tax Demand

The tax demand arose from the disallowance of certain expenses claimed by the company in its income tax return for Assessment Year 2024-25. The assessment order resulted in both the primary tax demand and potential penalties, bringing the total demand to Rs 4,81,61,360.

Company's Response Strategy

Jagsonpal Pharmaceuticals has outlined its response to the tax demand notice. The company plans to file an appeal against the assessment order before the concerned Appellate Authority within the prescribed timelines, along with any required pre-deposit.

Financial Impact Assessment

The company has expressed confidence in its position regarding the tax matter. Management believes it has merits in the case and does not expect any material impact on the company financially or otherwise. No penalties or restrictions have been imposed pursuant to the communication, and the company maintains that it will contest the demand through proper legal channels.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Pratham Rawal signed the regulatory filing, ensuring transparency with stakeholders about this significant development.

Jagsonpal Pharmaceuticals Limited has successfully approved its comprehensive share buyback proposal during the board meeting held on March 12, 2026. The pharmaceutical company's board has decided to repurchase up to 16 lakh equity shares at ₹250 per share through the tender offer route, with the total buyback value reaching ₹40 crores. The buyback price represents a premium of 40% to the current market price.

Buyback Approval and Structure

The board meeting, conducted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, resulted in formal approval of the buyback proposal. The decision encompasses all regulatory and procedural aspects required for implementation, subject to shareholder approval and other statutory approvals.

Financial Rationale and Cash Position

The company operates with an asset-light business model requiring minimal capital for scaling operations. Between FY22 to FY25, Jagsonpal added over ₹142 crores of free cash despite increased dividends and ₹95 crores deployed for acquisitions. As of December 31, 2025, the company maintains free cash of ₹176 crores.

Professional Advisory and Compliance Framework

The company has appointed Centrum Capital Limited, a SEBI registered Merchant Banker, as the Manager to the Buyback. A dedicated "Buyback Committee" has been constituted with delegated powers, including authority to fix the record date and undertake necessary actions for the proposed buyback.

Shareholding Impact and Promoter Strategy

A significant aspect of this buyback is the promoters' decision to abstain from participation entirely. This strategic choice ensures buyback benefits are concentrated among non-promoter shareholders, potentially increasing ownership concentration for participating public investors. Managing Director Manish Gupta emphasized the company's commitment to enhancing shareholder value and optimizing capital structure.

*Indicative figures assuming full buyback of 16 lakh shares

Implementation Timeline and Next Steps

The board meeting, which commenced at 1:00 PM and concluded at 1:45 PM, marks the formal approval stage of the buyback process. The company will separately intimate details regarding the postal ballot for seeking shareholder approval. The buyback excludes expenses such as brokerage costs, fees, securities transaction tax, and other incidental expenses from the maximum offer size calculation.